We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 164.80 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 164.80 | 165.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 164.80 | GBX |
Vectura (VEC) Share Charts1 Year Vectura Chart |
|
1 Month Vectura Chart |
Intraday Vectura Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/10/2021 | 11:03 | Vectura - An emerging Pharmaceutical Co. | 11,991 |
| 04/4/2006 | 20:42 | A winner. | 87 |
| 04/4/2006 | 09:05 | VECTURA HAS 20M AND DEVELOPS DRUGS | 6 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 28/9/2021 11:38 by saget Hi,Sorry but could someone help? I have have a bunch of Vectura shares in certificate form - initially invested in them 20 years ago when they were ML Labs, anyone remember them? And I paid a whopping £2 a share that I have been waiting to make back ever since. Guess I never will. I now realise that I need to send back a form with my share certificate in order to accept the current offer. Would anyone know which form that is please? I did manage to find a form for the recommended cash offer, along with a booklet for the ‘Recommended Cash Offer of 165 pence per Vectura Share for Vectura Group plc by PMI Global Services Inc.’ but it says the deadline for submitting it was 15th September. Do I still send this form back or is there another one that I should be using? Thanks in advance for any help! |
Posted at 09/8/2021 21:23 by a1ord53 Takeover PanelVectura Group plc - auction procedure RNS Number : 9904H Takeover Panel 09 August 2021 2021/16 OFFERS BY MURANO BIDCO LIMITED ("CARLYLE"), A COMPANY INDIRECTLY CONTROLLED BY FUNDS MANAGED BY CARLYLE EUROPE PARTNERS V AND PMI GLOBAL SERVICES INC. ("PMI"), A WHOLLY-OWNED SUBSIDIARY OF PHILIP MORRIS INTERNATIONAL INC. FOR VECTURA GROUP PLC ("VECTURA") Introduction On 26 May 2021, the boards of Vectura and Carlyle announced that they had reached agreement on the terms of a recommended cash acquisition pursuant to which Carlyle would acquire all of the issued and to be issued ordinary shares of Vectura at 136 pence per Vectura share (the "Carlyle Offer") to be implemented by means of a scheme of arrangement. On 18 June 2021, Vectura and Carlyle announced the publication of the scheme document related to the Carlyle Offer. On 9 July 2021, the boards of Vectura and PMI announced that they had reached agreement on the terms of a recommended cash acquisition pursuant to which PMI would acquire all of the issued and to be issued ordinary shares of Vectura at 150 pence per Vectura share (the "PMI Offer") to be implemented by means of a scheme of arrangement. Vectura also announced that it had withdrawn its recommendation of the Carlyle Offer. On 28 July 2021, Vectura and PMI announced the publication of the scheme document related to the PMI Offer. On 6 August 2021, the boards of Vectura and Carlyle further announced that they had reached agreement on the terms of a revised recommended cash offer at a price of 155 pence per Vectura share, to be implemented by means of a scheme of arrangement. Vectura also announced that it had withdrawn its recommendation of the PMI Offer. On 8 August 2021, the board of PMI announced a further increased cash offer at a price of 165 pence per Vectura share. On the basis that neither offeror has declared its offer final, such that either offer may be further increased or otherwise revised, a competitive situation continues to exist for the purposes of Rule 32.5 of the Takeover Code (the "Code"). In order to provide an orderly framework for the resolution of this competitive situation, and in accordance with Rule 32.5, the Panel Executive has, after discussions with the parties, established an auction procedure and determined that Day 46 for these purposes shall be Tuesday 10 August 2021. This is based upon the auction procedure set out in Appendix 8 of the Code, but has been adapted as noted below. Accordingly, assuming that a competitive situation continues to exist, the auction procedure is expected to commence at 5.00pm (London time) on Tuesday 10 August 2021: (a) "Auction Day 1" shall be Wednesday 11 August 2021; (b) "Auction Day 2" shall be Thursday 12 August 2021; (c) "Auction Day 3" shall be Friday 13 August 2021; (d) "Auction Day 4" shall be Monday 16 August 2021; and (e) "Auction Day 5" shall be Tuesday 17 August 2021. The auction procedure provides for up to five days of public bidding over sequential business days under which: (a) each offeror is permitted to announce a revised offer on any Auction Day and, as envisaged by paragraphs 4(b) and (c) of Appendix 8 of the Code, may also submit an offer announcement to the Panel Executive subject to a condition that the revised offer will be announced only if the other competing offeror also submits an offer announcement to the Panel Executive on that day; and (b) if neither offeror announces a revised offer on any Auction Day, the auction ends. As an adaptation to the procedure set out in Appendix 8 of the Code, a revised offer announced by either offeror during the auction procedure must be made at a price per share: (a) in cash in pounds sterling and in a whole number of pence; and (b) above the level of the offer most recently announced or made by the other offeror. As a further adaptation to the procedure set out in Appendix 8 of the Code, on Auction Day 5: (a) the offeror with the lowest offer at that point shall only be permitted to make an offer at an "odd" number of pence; and (b) the offeror with the highest offer at that point shall only be permitted to make an offer at an "even" number of pence. The Panel Executive has reserved the discretion to amend the auction procedure as appropriate. In particular, the dates referred to above may be subject to change, depending on the circumstances at the time. In the event of an amendment to the above dates, the Panel Executive will make a further statement. Save for a revised offer announced in accordance with the auction procedure, neither offeror will be permitted to announce or to make a revised offer for Vectura on or after 5.00pm on Tuesday 10 August 2021. Pursuant to section 2(i) of Appendix 8 of the Code, the Panel Executive will make an announcement confirming when the auction procedure has ended. Following the end of the auction procedure, save with the consent of the Panel Executive, neither offeror is permitted to revise the price of its offer for Vectura from that established by means of the auction procedure or to introduce any new alternative offer unless, under the normal provisions of the Code, a person other than (a) Carlyle or PMI or (b) any person acting in concert with either Carlyle or PMI announces a firm intention to make an offer for Vectura. If Vectura declares or pays a dividend between the conclusion of the auction procedure and the end of the offer period, each offeror will reduce the terms of its offer by an amount per share equal to the amount of the dividend per share. In the event that one of the offerors announces before the commencement of the auction procedure that it will not increase its offer, a competitive situation would no longer exist and so the auction procedure would not be required. If such an announcement is made before 5.00pm on Tuesday 10 August 2021, the other offeror will have until 5.00pm on Thursday 12 August 2021 to announce a revised offer. Each of Vectura, Carlyle and PMI has agreed to the terms of the auction procedure and this statement. 9 August 2021 |
Posted at 09/7/2021 11:09 by jimboyce Philip Morris Makes $1.24 Billion Bid for UK Respiratory Drugs Company -- UpdateSource: Dow Jones News--Philip Morris International plans to buy Vectura Group as part of expansion beyond tobacco products--Vectura board withdrew its recommendation of an earlier offer from Carlyle--Carlyle said it is considering its options By Adria Calatayud Philip Morris International Inc. plans to buy Vectura Group PLC, a U.K. pharmaceuticals business specializing in inhaled medicines, for 899.2 million pounds ($1.24 billion) in cash, bolstering its push to expand beyond tobacco and nicotine.Philip Morris International, which sells the Marlboro brand outside the U.S., on Friday said that Vectura will be the backbone of its inhaled-therapeutic business.The move from the tobacco company trumps an earlier bid for Vectura by Carlyle Group Inc., which had been recommended by the board of the U.K. company in May. Philip Morris's offer values Vectura at 150 pence a share, 10% higher than Carlyle's bid.In response, Carlyle said it is considering its options and encouraged Vectura shareholders to take no action.Shares in Vectura at 0928 GMT traded 13% higher at 153.60 pence.The offer from Philip Morris valued Vectura at GBP1.05 billion, or 169 pence a share, including a dividend of 19 pence a share the U.K. company paid in June.Philip Morris said the acquisition of Vectura is part of its evolution into a broader healthcare and wellness company. Earlier this year, it outlined plans to generate more than half of its revenue from smokeless products by 2025, up from 24% in 2020, in a bid to court ethical investors.Philip Morris said respiratory drug delivery and selfcare wellness products are key in its plans to move away from tobacco and nicotine and that Vectura's strengths can help it to tap into the fast-growing market for inhaled therapeutics."We see Vectura's combination of device, formulation and development capabilities for inhaled therapeutics as highly complementary to our existing expertise, pipeline and experience in aerosolization," Philip Morris Chief Executive Jacek Olczak said.Vectura, based in Chippenham, England, will operate as an autonomous business unit within Philip Morris with support for its current strategy, the companies said. In 2019, the company changed its strategy to focus on providing contracted drug-development services for partners.Analysts at brokerage Peel Hunt said Philip Morris's offer for Vectura reduces the likelihood of further bids from private-equity investors, as the U.K. company's plans to develop a contract development-and-manu |
Posted at 24/6/2021 07:25 by vecturaking (Alliance News) - Vectura Group PLC on Friday released scheme documents for its GBP958 million takeover by funds managed by private equity firm Carlyle Group Inc.The Wiltshire-based pharmaceutical company will hold general and court meetings on July 12 for shareholders to vote on the acquisition, which was agreed at the end of May. Vecture plans to hold a court hearing to sanction the scheme two weeks after regulatory conditions are met. The hearing is expected to be in the third quarter of 2021, with a long stop date of November 26. Trading in Vectura shares will be suspended the next day before being de-listed two days after the hearing. Vectura shares were trading flat at 136.61 pence each in London on Friday afternoon. Carlyle will pay 136p per share for Wiltshire-based drug maker Vectura, while shareholders will be entitled to a further 19p per share interim dividend. By Scarlett Butler; scarlettbutler@allia Copyright 2021 Alliance News Limited. All Rights Reserved. |
Posted at 21/6/2021 13:16 by gbcol IMO clearly not expected as share price has dropped from a circa 6p premium when it was first announced to below offer price now. If a better offer was expected share price would still be at a premium. Obviously I’d be delighted to be wrong and an enhanced is made. |
Posted at 26/5/2021 16:24 by a1ord53 I think shareprice is higher, because existing shareholders/today&#Example : for those who had bought at 122p or lower , today’s share price 162 p means average price under 155p will result in profit - so easy ) If no higher bid , current share price is great - gives 8 p additional premium ! |
Posted at 07/5/2021 18:13 by rolo7 Vec share price will increase after consolidation by one 5th its a 4/5 share consolidation? vec will remain in fste 250 this time next month. |
Posted at 27/4/2021 12:55 by gbcol Thanks guys.I got a quick response from IR, rather vague and global so I expect that they have had a few people querying it. Basically 3 points. First, that the value of my holding will not reduce overall as a result of the divi/consolidation. Whoppee-do. That’s the theory anyway, we’ll see. Not a reason for doing it though, in any case. Second, without consolidation, divi would adversely affect the share price chart. Thirdly, that share consolidations usually increases the share price - which I would seriously question. Possibly there might be something in the increase in EPS that Polaris mentioned but I’m struggling for a reason to vote for it. Mine are held in SIPP & ISA so no tax issues for me but I’m not sure if I’d be able to take advantage of the DRIP (will have to check with them). So, if not and I believe share price should be above current levels - which I do - I’ll have to buy back my reduced holding on the open market. Personally I would have gone for a small divi and maybe some buybacks but guess were stuck with this now. |
Posted at 22/3/2021 13:42 by richman777114 polaris,one could almost imagine a lid is being kept on the VEC share price to make a circa 140p offer look attractive to weary shareholdersIMHO |
Posted at 20/3/2021 08:49 by a1ord53 FT:“Share price forecast The 6 analysts offering 12 month price targets for Vectura Group PLC have a median target of 132.00, with a high estimate of 149.00 and a low estimate of 126.00. The median estimate represents a 14.58% increase from the last price of 115.20 29.3% from 149.00 Med 14.6% from 132.00 Low 9.4% from 126.00 .” PS The lowest Price Target 10% higher than current price. Imo after GSK petition expiry and divi date announcement end of April, Advair approval share price will move above 130-35 p fast. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
